Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 5
Submit an article Journal homepage
542
Views
1
CrossRef citations to date
0
Altmetric
Author's View

Combining forces to hit cancer stem cells

TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

Ingrid Herr Molecular OncoSurgery Group; University of Heidelberg and German Cancer Research Center; Heidelberg, GermanyCorrespondence[email protected]
,
Ariane Groth University of Frankfurt; Institute of Biomedical Research; Georg-Speyer-Haus; Frankfurt, Germany
,
Alexei V. Salnikov Molecular OncoSurgery Group; University of Heidelberg and German Cancer Research Center; Heidelberg, Germany; Department of Translational Immunology; German Cancer Research Center and National Center for Tumor Diseases; Heidelberg, Germany
,
Markus W. Buchler Department of General Surgery; University of Heidelberg and German Cancer Research Center; Heidelberg, Germany
&
Gerhard Moldenhauer Department of Translational Immunology; German Cancer Research Center and National Center for Tumor Diseases; Heidelberg, Germany
Pages 741-743 | Published online: 24 Aug 2012

References

  • McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 2001; 61:4105 - 11; PMID: 11358833
  • Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209 - 21; http://dx.doi.org/10.1002/ijc.25423; PMID: 20473913
  • Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, et al. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med 2009; 13:9B 4023 - 33; http://dx.doi.org/10.1111/j.1582-4934.2009.00723.x; PMID: 20196789
  • Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002; 101:183 - 9; http://dx.doi.org/10.1002/ijc.10562; PMID: 12209996
  • Groth A, Salnikov AV, Ottinger S, Gladkich J, Kallifatidis G, Salnikova O, et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res 2012; In press http://dx.doi.org/10.1158/1078-0432.CCR-11-2767; PMID: 22228630
  • Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells. Clin Cancer Res 2012; 18:465 - 74; PMID: 22096026
  • Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25:1390 - 5; http://dx.doi.org/10.1200/JCO.2006.08.8898; PMID: 17416859
  • Hoffmann SC, Wabnitz GH, Samstag Y, Moldenhauer G, Ludwig T. Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer 2011; 128:2096 - 104; http://dx.doi.org/10.1002/ijc.25556; PMID: 20635391
  • Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282 - 6; http://dx.doi.org/10.1038/nature08296; PMID: 19741708

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.